亚毫西弗胸部与腹部CT深度学习重建与迭代重建的图像质量和病灶检出比较
前瞻性多机构研究纳入59例成人,在常规标准剂量CT后追加亚毫西弗低剂量CT,比较深度学习重建(DLR)与迭代重建(IR)及滤波反投影(FBP)的图像质量和临床显著病灶检出。低剂量DLR图像上全部31个腹部病灶和39个肺结节均被检出,图像质量可接受率达腹部97%、胸部95-100%。结论为在亚毫西弗剂量下DLR的图像质量和病灶检出优于商用IR和FBP。
要点
- 低剂量DLR上全部31个腹部临床显著病灶和39个肺结节均被检出,与标准剂量AIDR 3D一致。
- 低剂量AIDR 3D、FIRST和FBP分别仅检出25、18和7个腹部病灶。
- 低剂量DLR图像被判定可解读的比例为腹部97%(35/37)、胸部95-100%(21-22/22)。
核心结论
- 在亚毫西弗胸腹部CT剂量下,DLR的图像质量和病灶检出优于商用IR和FBP图像。
研究设计与样本
- 前瞻性多机构研究,纳入59例成人(女33例、男26例,平均年龄65±12岁,平均体重指数27±5)。
- 胸部CT 22例(女16例、男6例),腹盆部CT 37例(女17例、男20例),均使用640层MDCT(Aquilion ONE,Canon Medical Systems)。
- 所有患者先接受临床指示的标准剂量CT(120 kVp,164-644 mA,AIDR 3D重建),再在知情同意下追加低剂量CT(100 kVp或120 kVp,30-50 mA)。
- 低剂量CT分别用FBP、AIDR 3D、FIRST和DLR(AiCE)重建。
- 由4名亚专科培训的放射科医师先独立盲法随机阅读全部低剂量图像,再与标准剂量AIDR 3D图像并排比较;图像质量按3分制评估(1=不可接受,2=欠佳,3=最佳),采用Wilcoxon符号秩检验。
关键影像表现/征象
- 低剂量DLR图像上全部31个临床显著腹部病灶均可见,与标准剂量AIDR 3D一致。
- 低剂量DLR图像上标准剂量AIDR 3D检出的全部39个肺结节均被检出。
- 低剂量AIDR 3D、FIRST和FBP图像分别检出25、18和7个腹部病灶。
诊断标准与关键数值
- 图像质量3分制:1=不可接受,2=欠佳,3=最佳。
- 低剂量CT平均容积CT剂量指数和剂量长度乘积分别为2.1±0.8 mGy和49±13 mGy·cm,低于标准剂量CT的13±4.4 mGy和567±249 mGy·cm(p<0.0001)。
- 低剂量DLR图像可接受判读的比例为腹部97%(35/37)、胸部95-100%(21-22/22)(p=0.2-0.99)。
- 低剂量FIRST、AIDR 3D和FBP图像质量均低于标准剂量AIDR 3D图像(p<0.0001)。
临床应用与阅片要点
- 在亚毫西弗胸腹部CT中,低剂量DLR图像可达到与标准剂量AIDR 3D相当的临床显著病灶检出。
- 低剂量FBP和IR图像上腹部病灶检出明显减少,阅片时需注意其假阴性可能。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVE. The objective of this study was to compare image quality and clinically significant lesion detection on deep learning reconstruction (DLR) and iterative reconstruction (IR) images of submillisievert chest and abdominopelvic CT. MATERIALS AND METHODS. Our prospective multiinstitutional study included 59 adult patients (33 women, 26 men; mean age ± SD, 65 ± 12 years old; mean body mass index [weight in kilograms divided by the square of height in meters] = 27 ± 5) who underwent routine chest (n = 22; 16 women, six men) and abdominopelvic (n = 37; 17 women, 20 men) CT on a 640-MDCT scanner (Aquilion ONE, Canon Medical Systems). All patients gave written informed consent for the acquisition of low-dose (LD) CT (LDCT) after a clinically indicated standard-dose (SD) CT (SDCT). The SDCT series (120 kVp, 164-644 mA) were reconstructed with interactive reconstruction (IR) (adaptive iterative dose reduction [AIDR] 3D, Canon Medical Systems), and the LDCT (100 kVp, 120 kVp; 30-50 mA) were reconstructed with filtered back-projection (FBP), IR (AIDR 3D and forward-projected model-based iterative reconstruction solution [FIRST], Canon Medical Systems), and deep learning reconstruction (DLR) (Advanced Intelligent Clear-IQ Engine [AiCE], Canon Medical Systems). Four subspecialty-trained radiologists first read all LD image sets and then compared them side-by-side with SD AIDR 3D images in an independent, randomized, and blinded fashion. Subspecialty radiologists assessed image quality of LDCT images on a 3-point scale (1 = unacceptable, 2 = suboptimal, 3 = optimal). Descriptive statistics were obtained, and the Wilcoxon sign rank test was performed. RESULTS. Mean volume CT dose index and dose-length product for LDCT (2.1 ± 0.8 mGy, 49 ± 13mGy·cm) were lower than those for SDCT (13 ± 4.4 mGy, 567 ± 249 mGy·cm) (p < 0.0001). All 31 clinically significant abdominal lesions were seen on SD AIDR 3D and LD DLR images. Twenty-five, 18, and seven lesions were detected on LD AIDR 3D, LD FIRST, and LD FBP images, respectively. All 39 pulmonary nodules detected on SD AIDR 3D images were also noted on LD DLR images. LD DLR images were deemed acceptable for interpretation in 97% (35/37) of abdominal and 95-100% (21-22/22) of chest LDCT studies (p = 0.2-0.99). The LD FIRST, LD AIDR 3D, and LD FBP images had inferior image quality compared with SD AIDR 3D images (p < 0.0001). CONCLUSION. At submillisievert chest and abdominopelvic CT doses, DLR enables image quality and lesion detection superior to commercial IR and FBP images.
引用
- Singh R, Digumarthy SR, Muse VV, et al. Image Quality and Lesion Detection on Deep Learning Reconstruction and Iterative Reconstruction of Submillisievert Chest and Abdominal CT. AJR Am J Roentgenol. 2020. PMID: 31967501. doi:10.2214/AJR.19.21809
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。